# Title

 Food and Drugs. PART 50â€”PROTECTION OF HUMAN SUBJECTS


# ID

 CFR-2018-title21-vol1.Pt. 50


# Structured Analysis Summary

| Type        | Values                                                                                                                                    |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['at most', 'before', 'within', 'more than', 'not to exceed', 'greater than', 'after', 'at least', 'greater', 'prior to', 'no more than'] |
| Duration    | ['3.0 year', '1 year']                                                                                                                    |
| Condition   | ['not subject to', 'unless', 'as soon as', 'where', 'subject to', 'when', 'if']                                                           |
| Entities    | ['Test', 'Additional', 'Scope', 'Clinical', 'Spouse', 'Food', 'Children', 'Defense', 'U.S. Law', 'Guardian']                              |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------------------|
| greater       | or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered                       |
| before        | of informed consent shall be deemed feasible unless, before use of the test article (except as provided                                |
| greater       | generally recognized therapy that provides an equal or greater  likelihood of saving the life of the subject.                          |
| within        | of the clinical investigator shall be made and, within 5 working days after the use of the                                             |
| after         | shall be made and, within 5 working days after the use of the article, be reviewed and                                                 |
| within        | this section shall be submitted to the IRB within 5 working days after the use of the                                                  |
| after         | submitted to the IRB within 5 working days after  the use of the test article.                                                         |
| prior to      | made that obtaining informed consent from military personnel prior to the use of an investigational drug (including an                 |
| prior to      | involved in the military operation will be given, prior to the administration of the investigational new drug, a                       |
| prior to      | the specific investigational new drug to be administered prior to  its use.                                                            |
| not to exceed | time period for which the waiver is needed, not to exceed one year, unless separately renewed under these standards                    |
| at least      | in paragraph (d)(1)(v) of this section, must include at least 3 nonaffiliated members who shall not be employees                       |
| at least      | a majority of the members are present including at least one member whose primary concerns are in nonscientific                        |
| before        | or nuclear agents will be deemed feasible unless, before use of the test article, both the investigator                                |
| greater       | or nuclear agent that provides an equal or greater  likelihood of saving the life of the subject.                                      |
| within        | determinations of the investigator shall be made and, within 5 working days after the use of the                                       |
| after         | shall be made and, within 5 working days after the use of the device, be reviewed and                                                  |
| within        | of this section to the IRB and FDA within 5 working days after the use of the                                                          |
| after         | the IRB and FDA within 5 working days after  the use of the device.                                                                    |
| before        | or other requirement that informed consent be obtained before an investigational in vitro diagnostic device may be                     |
| before        | (ii) The intervention under investigation must be administered before consent from the subjects' legally authorized representatives is |
| within        | contact a legally authorized representative for each subject within that window of time and, if feasible, to                           |
| within        | contact a legally authorized representative for each subject within that window of time and, if feasible, to                           |
| prior to      | and from which the subjects will be drawn, prior to initiation of the clinical investigation, of plans for                             |
| within        | has committed, if feasible, to attempting to contact within the therapeutic window the subject's family member who                     |
| before        | investigation with waived consent and the subject dies before a legally authorized representative or family member can                 |
| at least      | are to be retained by the IRB for at least 3 years after completion of the clinical investigation,                                     |
| after         | by the IRB for at least 3 years after completion of the clinical investigation, and the records                                        |
| more than     | (6) For research involving  more than minimal risk, an explanation as to whether any                                                   |
| at most       | site will include a summary of the results. at most                                                                                    |
| before        | or the representative adequate opportunity to read it before  it is signed.                                                            |
| greater than  | of this subpart D. Clinical investigations not involving greater than  minimal risk.                                                   |
| within        | Any clinical investigation  within the scope described in &#167;&#167;&#8201;50.1 and 56.101 of                                        |
| greater than  | and 56.101 of this chapter in which no greater than minimal risk to children is presented may involve                                  |
| greater than  | and 56.101 of this chapter in which no greater than minimal risk to children is presented may involve                                  |
| greater than  | Clinical investigations involving  greater than minimal risk but presenting the prospect of direct                                     |
| within        | Any clinical investigation  within the scope described in &#167;&#167;&#8201;50.1 and 56.101 of                                        |
| more than     | &#167;&#167;&#8201;50.1 and 56.101 of this chapter in which more than minimal risk to children is presented by an                      |
| at least      | of the anticipated benefit to the risk is at least as favorable to the subjects as that presented                                      |
| greater than  | Clinical investigations involving  greater than minimal risk and no prospect of direct benefit                                         |
| within        | Any clinical investigation  within the scope described in &#167;&#167;&#8201;50.1 and 56.101 of                                        |
| more than     | &#167;&#167;&#8201;50.1 and 56.101 of this chapter in which more than minimal risk to children is presented by an                      |
| within        | IRB does not believe that a clinical investigation within the scope described in &#167;&#167;&#8201;50.1 and 56.101 of                 |
| after         | and (b) The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent                                    |
| no more than  | and documents that: (1) The clinical investigation involves no more than minimal risk to the subjects; (2) The waiver                  |
| after         | subjects will be provided with additional pertinent information after  participation.                                                  |
| more than     | (2) One individual may serve as advocate for  more than  one child.                                                                    |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                  |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 year     | (xv) DOD has stated and justified the time period for which the waiver is needed, not to exceed one year, unless separately renewed under these standards and criteria.                                                                                                                                                                                                  |
| 3.0 year   | (c) The IRB determinations required by paragraph (a) of this section and the documentation required by paragraph (e) of this section are to be retained by the IRB for at least 3 years after completion of the clinical investigation, and the records shall be accessible for inspection and copying by FDA in accordance with &#167;&#8201;56.115(b) of this chapter. |


## Condition

| Condition      | Context                                                                                                                                        |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|
| unless         | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                             |
| when           | about a clinical study of an infant formula when submitted as part of an infant formula notification                                           |
| subject to     | or more human subjects and that either is subject to requirements for prior submission to the Food and                                         |
| not subject to | 505(i) or 520(g) of the act, or is not subject to requirements for prior submission to the Food and                                            |
| subject to     | The term does not include experiments that are  subject to the provisions of part 58 of this chapter,                                          |
| subject to     | color additive, electronic product, or any other article subject to regulation under the act or under sections 351                             |
| subject to     | law to consent on behalf of a prospective subject to the subject's particpation in the procedure(s) involved in                                |
| unless         | a subject in research covered by these regulations unless the investigator has obtained the legally effective informed                         |
| unless         | obtaining of informed consent shall be deemed feasible unless , before use of the test article (except                                         |
| if             | the investigator's opinion, required to preserve the l if e of the subject, and time is not                                                    |
| if             | The statute spec if ies that only the President may waive informed                                                                             |
| subject to     | a substantial risk that military personnel may be subject to a chemical, biological, nuclear, or other exposure likely                         |
| subject to     | that the investigational new drug protocol may proceed subject to a decision by the President on the informed                                  |
| unless         | waiver is needed, not to exceed one year, unless  separately renewed under these standards and criteria.                                       |
| as soon as     | (xvii) DOD is to provide public notice  as soon as practicable and consistent with classification requirements through notice                  |
| if             | one member whose primary concerns are in nonscient if ic areas and,                                                                            |
| unless         | radiological, or nuclear agents will be deemed feasible unless , before use of the test article, both                                          |
| if             | other responsible person), required to preserve the l if e of the subject, and time is not                                                     |
| if             | informed consent of all research subjects be obtained if the IRB (with the concurrence of a licensed                                           |
| if             | subjects because: (i) Subjects are facing a l if e-threatening situation that necessitates intervention; (ii) Appropriate animal               |
| if             | of the potential therapeutic window based on scient if ic evidence, and the investigator has committed to                                      |
| where          | subjects or their legally authorized representatives in situations where  use of such procedures and documents is feasible.                    |
| when           | and approved procedures and information to be used when providing an opportunity for a family member to                                        |
| where          | be provided, including, at least: (i) Consultation (including, where appropriate, consultation carried out by the IRB) with                    |
| if             | is not reasonably available, the investigator has committed, if feasible, to attempting to contact within the therapeutic                      |
| if             | is not reasonably available, the investigator has committed, if feasible, to attempting to contact within the therapeutic                      |
| if             | at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, a legally authorized representative               |
| if             | at the earliest feasible opportunity, each subject, or if the subject remains incapacitated, a legally authorized representative               |
| if             | is a procedure to inform the subject, or if the subject remains incapacitated, a legally authorized representative                             |
| if             | is a procedure to inform the subject, or if the subject remains incapacitated, a legally authorized representative                             |
| as soon as     | improves, the subject is also to be informed as soon as  feasible.                                                                             |
| if             | the subject's legally authorized representative or family member, if  feasible.                                                                |
| if             | protocols in a separate IND/IDE is required even if an IND for the same drug product or                                                        |
| if             | and to the sponsor of the clinical investigation. if                                                                                           |
| if             | of appropriate alternative procedures or courses of treatment, if  any, that might be advantageous to the subject.                             |
| if             | (5) A statement describing the extent,  if  any, to which confidentiality of records ident                                                     |
| if             | as to whether any medical treatments are available if  injury occurs and,                                                                      |
| if             | as to whether any medical treatments are available if  injury occurs and,                                                                      |
| where          | and, if so, what they consist of, or where  further information may be obtained.                                                               |
| if             | the subject (or to the embryo or fetus, if the subject is or may become pregnant) which                                                        |
| when           | trial subject in informed consent documents and processes. when                                                                                |
| if             | is presented may involve children as subjects only if the IRB finds that: (a) No greater than                                                  |
| if             | subject's well-being, may involve children as subjects only if the IRB finds that: (a) The risk is                                             |
| if             | the subject, may involve children as subjects only if the IRB finds that: (a) The risk represents                                              |
| when           | made for soliciting the assent of the children when in the judgment of the IRB the children                                                    |
| if             | necessary condition for proceeding with the clinical investigation if the IRB determines: (1) That the capability of                           |
| where          | (d) Even  where the IRB determines that the subjects are capable                                                                               |
| if             | the IRB may still waive the assent requirement if it finds and documents that: (1) The clinical                                                |
| where          | investigations to be conducted under &#167;&#8201;50.51 or &#167;&#8201;50.52. where                                                           |
| where          | for the care and custody of the child. where                                                                                                   |
| unless         | from parents, both parents must give their permission unless one parent is deceased, unknown, incompetent, or not                              |
| when           | deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal responsibility for the                          |
| when           | determine whether and how assent must be documented. when                                                                                      |
| if             | clinical investigations approved under &#167;&#8201;50.53 or &#167;&#8201;50.54 only if such clinical investigations are: (1) Related to their |
| if             | advocate for each child who is a ward. if                                                                                                      |


## Entities

| Entities   | Context                                                                                                                         |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------|
| Food       | Food  and Drugs.                                                                                                                |
| Scope      | Scope .                                                                                                                         |
| Additional | Additional specific obligations and commitments of, and standards of                                                            |
| Test       | (j)  Test article means any drug (including a biological product                                                                |
| Spouse     | any one of the following legally competent persons: Spouse ; parents; children (including adopted children); brothers, sisters, |
| Children   | (o)  Children means persons who have not attained the legal                                                                     |
| Guardian   | (s)  Guardian means an individual who is authorized under applicable                                                            |
| Defense    | drug application (IND) sponsored by the Department of Defense (DOD) and limited to specific military personnel involved         |
| U.S. Law   | will be available on http://www.ClinicalTrials.gov, as required by U.S. Law .                                                   |
| Clinical   | Clinical investigations involving greater than minimal risk but presenting                                                      |
| Clinical   | Clinical investigations involving greater than minimal risk and no                                                              |
| Clinical   | Clinical investigations not otherwise approvable that present an opportunity                                                    |
| Food       | welfare of children; and (b) The Commissioner of Food and Drugs, after consultation with a panel of                             |


